Tempus AI

Comprehensive genomic profiling value extends beyond panel size. Advanced testing features like RNA sequencing and tumor + normal match can expand treatment and clinical trial options while helping to better capture clinically relevant findings. Learn more about how our comprehensive genomic profiling solutions are transforming the way cancer is diagnosed and treated: https://tempus.co/4sY49WI

Researchers utilized Tempus Lens to investigate whether KRAS mutant allele dosage correlates with first-line (1L) treatment outcomes and tumor microenvironment (TME) changes. Findings underscore the potential benefit of incorporating allelic dosage into clinical trial design to ensure unbiased assessments of therapeutic efficacy by balancing dosage across study arms. Explore this study, and other real-world case studies, in the Lens Library now: https://tempus.co/4bX0UY8

We're excited to share results from the ALERT trial, conducted in collaboration with Medtronic. The study found that automated electronic clinician notifications (ECNs) integrated into the electronic health record (EHR) significantly improve the timely evaluation and treatment of patients with significant aortic stenosis (AS) and mitral regurgitation (MR). The ALERT Trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems and 35 hospitals. ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease and accelerate time to treatment. Learn more: https://tempus.co/4dR0Njm

We are looking forward to attending the World CB & CDx Summit Europe 2026 to share how Tempus can support strategic CDx development through to commercialization. Meet with the team at Booth #16 or attend Andrew Paramore's presentation on March 31 at 15:00–15:30 GMT. This live session will cover: ▪️ Establishing a foundation for market access through in-country clinical utility studies and operational investment. ▪️Utilizing Al-powered digital pathology to create a more efficient and cost-effective path to NGS testing. ▪️Pioneering collaborative commercial models to remove access barriers and accelerate diagnostic adoption.

Unlocking the power of precision medicine starts with data. With data that is representative, connected, and multimodal, you can uncover new insights that can help change the trajectory of a drug's development. With Tempus, you can move faster, go further, and reach more patients. Explore our data offerings now: https://tempus.co/41zmjSc

We're looking forward to seeing you at American College of Cardiology's 75th Annual Scientific Session & Expo 2026. Meet with the Tempus team at Booth #1712 to discover how we are leading the adoption of Al to help providers close care gaps for patients who may have undiagnosed or undertreated cardiovascular disease. Attend our live session on Sunday, March 29 to learn more about the ALERT trial, which aims to address the significant gaps in the recognition and management of severe AS and MR which if left untreated leads to increased morbidity and mortality. https://tempus.co/40Qkwbl

Today we announced a collaborations with Daiichi Sankyo US aimed at accelerating the clinical development and differentiation of an antibody drug conjugate (ADC) program in oncology. By combining clinical trial and preclinical research data from Daiichi Sankyo with Tempus’ comprehensive real-world data, the collaboration aims to unlock new opportunities for biomarker discovery and patient stratification. Learn more: https://tempus.co/4sCWpJm

This fall, leaders from Tempus and Recursion came together for a webinar to explore their strategic TechBio partnership. Sid Jain, Hayley Donnella, Ph.D., and Shane Woods, Ph.D. discussed they use #AI and supercomputing with petabytes of data to accelerate drug discovery and development. Access the full recording to hear the impact on biopharma R&D's future: https://tempus.co/4bwxOjv

Join us for an upcoming webinar with Razik Yousfi, Arpita S., and SIQI LIU, to explore how foundation models move beyond single-purpose #AI to answer broader, more complex biological observations. Attendees will gain insights on our unique pathway from building a proof-of-concept model to deploying it directly into the clinic. Register now: https://tempus.co/4sfvenI

Join Tempus at the USCAP - United States and Canadian Academy of Pathology Annual Meeting to explore our comprehensive pathology offerings and latest research. Combining Paige’s industry-leading digital pathology expertise with the broader Tempus ecosystem, we are redefining what’s possible in AI-enabled pathology to empower anatomic and molecular pathologists worldwide. Head to booth #542 and learn more here: https://tempus.co/4rFuxms #USCAP2026